Phase 4
Completed N=31
Comparison of SoloSTAR With a Syringe-administered Glargine Insulin in Diabetic Patients From the Hospital
Source: ClinicalTrials.gov NCT01203774 ↗Enrolled (actual)
31
Serious AEs
0.0%
Results posted
Aug 2021
Primary outcomePrimary: HbA1c at Three Months of Each Period of Treatment — 10.7; 11.2; 7.8; 7.3 percentage (DCCT unit)
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
In this study the investigators would like to test the hypothesis that in diabetic patients discharged from the hospital, SoloSTAR Glargine insulin will be superior to syringe-injected Glargine in terms of diabetes control, compliance, and patient satisfaction and preference. The investigators will test this hypothesis in a randomized, crossover trial.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY HbA1c at Three Months of Each Period of Treatment |
10.7; 11.2; 7.8; 7.3; 8.5; 7.1 | — |
| SECONDARY Compliance and Patient Satisfaction |
— | — |
Eligibility Criteria
Inclusion Criteria
- All patients with type 1 and 2 diabetes discharged from the hospital with recommendations to take Glargine
Exclusion Criteria
- Patients unwilling to participate and patients incapable of complying with the study regimen, such as patients with alcohol and drug addiction problems and patients with severe mental illness
Data sourced from ClinicalTrials.gov (NCT01203774). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.